Background: Anticoagulation (AC) is used for stroke prevention in atrial fibrillation (AF). Direct Oral Anticoagulants (DOACs) are safe in patients with AF without cirrhosis, they are hardly studied in patients with advanced cirrhosis. Our study evaluates the safety and outcomes of DOACs in patients with Child-Pugh class C cirrhosis (CPC).
Methods: We queried TriNetX Database. Patients with CPC and AF were divided into three cohorts: patients on DOACs, no AC, and warfarin. Three study arms were created using a 1:1 propensity score matching system (PSM).
Results: Totally 16 029 patients met the inclusion criteria. Of those, 20.2% ( = 3235) were on DOACs, 47.1% ( = 7552) were not on AC, and 32.7% ( = 5242) were on warfarin. First arm comparing AC no AC, a statistically significant benefit was identified in 3-year mortality risk (47% 71%, < 0.0001) and transplant status (17% 5%, p < 0.0001) with AC. However, no significant difference was identified regarding intracranial hemorrhage and GI bleeding risk. Second arm comparing patients on DOACs no AC, we identified mortality benefit (40% 72%, < 0.0001) and a higher transplant rate (9% 3.2%, < 0.0001) with DOACs. Intracranial hemorrhage rates (6% 4%, = 0.03) were higher in patients on DOACs. Third arm comparing patients on DOACs Warfarin, a statistically significant lower risk of intracranial hemorrhage (6.6% 8.7%, = 0.004) and GI bleed (2% 2.4%, < 0.0001) were identified in patients on DOACs.
Conclusion: Anticoagulation is safe in patients with CPC with AF and may provide a mortality benefit. DOACs are a safer alternative to warfarin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11063728 | PMC |
| http://dx.doi.org/10.1002/jgh3.13074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of delayed adoption of novel atrial fibrillation treatments.
Am J Manag Care
December 2024
Center for Healthcare Economics and Policy, FTI Consulting, 350 S Grande Ave, Los Angeles, CA 90071. Email:
Objective: To examine the relationship between adoption of direct oral anticoagulants (DOACs) and health and cost outcomes for patients with nonvalvular atrial fibrillation.
Study Design: Real-world cohort study.
Methods: US adults who newly initiated treatment for nonvalvular atrial fibrillation were identified from claims data.
Comparative Outcomes of Warfarin vs. Direct Oral Anticoagulants (DOACs) in Anticoagulant-Related Gastrointestinal Bleeding: A Single-Center Study.
Cureus
December 2024
Medicine and Surgery, Khyber Medical University, Peshawar, PAK.
Background: The management of thromboembolic risk and the necessity for timely hemorrhage control make anticoagulant-related gastrointestinal (GI) bleeding clinically challenging.
Objective: This study aimed to evaluate clinical outcomes (such as bleeding control and mortality) and the effectiveness of anticoagulation reversal techniques in patients with anticoagulant-related GI bleeding in emergency settings.
Methodology: This prospective, observational study conducted at Lady Reading Hospital, Peshawar, from January to December 2023, included patients aged 18 or older with GI bleeding on warfarin or direct oral anticoagulants (DOACs).
Trends and cost structure of drug-based secondary prevention of ischemic strokes.
Neurol Res Pract
January 2025
Goethe University Frankfurt, University Hospital, Department of Neurology, Schleusenweg 2-16, 60528, Frankfurt am Main, Germany.
Background: Advances in secondary stroke prevention, including direct oral anticoagulants (DOACs), dual antiplatelet therapies (DAPT), and cardiovascular risk management, have changed costs over the past decade. This study aimed to evaluate annual treatment costs and trends in drug-based secondary prophylaxis after ischemic strokes.
Methods: Annual treatment costs were evaluated using the net costs per defined daily dosage (DDD) of discharge medications for ischemic stroke patients treated in 2020 at the University Hospital Frankfurt, Germany.
Anticoagulation approach in morbid obesity: a comprehensive review on venous thromboembolism management.
Front Pharmacol
December 2024
2nd Internal Medicine Department, Sf. Spiridon Clinical Emergency Hospital, Iasi, Romania.
Obesity is a recognized risk factor for venous thromboembolism (VTE), associated with distinct challenges in managing anticoagulation therapy. There is still limited evidence regarding the impact of extreme body weight on the pharmacokinetics, pharmacodynamics, efficacy, and safety of various anticoagulant medications. To our knowledge, this is the first comprehensive review to address both prophylactic and therapeutic anticoagulant dosages specifically for managing VTE in patients with a body mass index (BMI) ≥40 kg/m or weight ≥120 kg.
View Article and Find Full Text PDFPrevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial.
Thromb Haemost
December 2024
Department of Brain Sciences, Imperial College London, London, United Kingdom.
Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!